The following diagram for a crossover study does not use the crossing slanted lines sometimes used to represent crossover studies, because the order of the blocks is sufficient to represent the design of the study. Slanted lines are used only to represent the branch point at randomization, when a subject is assigned to a sequence of study product exposures. As in most crossover studies, the arms are distinguished by the order of study product exposures, with the same study product exposure present in each arm. Note that even though all 3 arms of this study end with the same block (i.e., the block for the follow-up element), the diagram does not show the arms converging into one block. Also note that the same block (the "rest" element) occurs twice within each arm. Elements are conceived of as "reusable" and can appear in more than 1 arm, in more than 1 epoch, and more than once in an arm.
| Excerpt Include |
|---|
| Example Study 2, Crossover Trial Study Schema |
|---|
| Example Study 2, Crossover Trial Study Schema |
|---|
|
| Include Page |
|---|
| Example Study 2, Crossover Trial Study Schema |
|---|
| Example Study 2, Crossover Trial Study Schema |
|---|
|
The next diagram for this crossover study shows the prospective view of the study; it identifies the epoch and arms of the study, and gives each a name. As for most crossover studies, the objectives of the study will be addressed by comparisons between the arms and by within-subject comparisons between study product exposures. Because the design depends on differentiating the periods during which the subject receives the 3 different study product exposures, there are 3 different study product exposure epochs. The fact that the rest periods are identified as separate epochs suggests that these also play an important part in the design of the study; they are probably designed to allow subjects to return to “baseline,” with data collected to show that this occurred. Note that epochs are not considered reusable; each epoch has a different name, even though all the study product exposure epochs are similar and both the rest epochs are similar. As with the first example study, there is a one-to-one relationship between the epochs of the study and the elements in each arm.
| Excerpt Include |
|---|
| Example Study 2, Crossover Study Prospective View |
|---|
| Example Study 2, Crossover Study Prospective View |
|---|
|
| Include Page |
|---|
| Example Study 2, Crossover Study Prospective View |
|---|
| Example Study 2, Crossover Study Prospective View |
|---|
|
The next diagram shows the retrospective view of the study.
| Excerpt Include |
|---|
| Example Study 2, Crossover Trial Retrospective View |
|---|
| Example Study 2, Crossover Trial Retrospective View |
|---|
|
| Include Page |
|---|
| Example Study 2, Crossover Trial Retrospective View |
|---|
| Example Study 2, Crossover Trial Retrospective View |
|---|
|
The last diagram for this study shows the study from the viewpoint of blinded participants. As in the simple parallel study in Example Study 1, blinded participants see only 1 sequence of elements; during the product exposure epochs they do not know which of the product exposure elements a subject is in.
| Excerpt Include |
|---|
| Example Study 2, Crossover Study Blinded View |
|---|
| Example Study 2, Crossover Study Blinded View |
|---|
|
| Include Page |
|---|
| Example Study 2, Crossover Study Blinded View |
|---|
| Example Study 2, Crossover Study Blinded View |
|---|
|
The following table illustrates the study design matrix for this crossover example study. It corresponds closely to the preceding retrospective diagram.
Trial Design Matrix
| Screen | First Study Product Exposure | First Rest | Second Study Product Exposure | Second Rest | Third Study Product Exposure | Follow-up |
|---|
| U-A-B | Screen | Usual Tobacco Product | Rest | Tobacco Product A | Rest | Tobacco Product B | Follow-up |
|---|
| A-U-B | Screen | Tobacco Product A | Rest | Usual Tobacco Product | Rest | Tobacco Product B | Follow-up |
|---|
| B-A-U | Screen | Tobacco Product B | Rest | Tobacco Product A | Rest | Usual Tobacco Product | Follow-up |
|---|
It is straightforward to produce the TA dataset for this crossover study from the diagram showing arms and epochs, or from the design matrix.
| Dataset wrap |
|---|
|
| Dataset2 |
|---|
| Row | STUDYID | DOMAIN | ARMCD | ARM | TAETORD | ETCD | ELEMENT | TABRANCH | TATRANS | EPOCH |
|---|
| 1 | EX2 | TA | U-A-B | UTP-TPA-TPB | 1 | SCRN | Screen | Randomized to UTP -TPA-TPB |
| SCREENING | | 2 | EX2 | TA | U-A-B | UTP-TPA-TPB | 2 | UTP | Usual |
|
| STUDY PRODUCT EXPOSURE 1 | | 3 | EX2 | TA | U-A-B | UTP-TPA-TPB | 3 | REST | Rest |
|
| WASHOUT 1 | | 4 | EX2 | TA | U-A-B | UTP-TPA-TPB | 4 | TPA | Prod A |
|
| STUDY PRODUCT EXPOSURE 2 | | 5 | EX2 | TA | U-A-B | UTP-TPA-TPB | 5 | REST | Rest |
|
| WASHOUT 2 | | 6 | EX2 | TA | U-A-B | UTP-TPA-TPB | 6 | TPB | Prod B |
|
| STUDY PRODUCT EXPOSURE 3 | | 7 | EX2 | TA | U-A-B | UTP-TPA-TPB | 7 | FU | Follow-up |
|
| FOLLOW-UP | | 8 | EX2 | TA | A-U-B | TPA-UTP-TPB | 1 | SCRN | Screen | Randomized to TPA- UTP- TPB |
| SCREENING | | 9 | EX2 | TA | A-U-B | TPA-UTP-TPB | 2 | TBA | Prod A |
|
| STUDY PRODUCT EXPOSURE 1 | | 10 | EX2 | TA | A-U-B | TPA-UTP-TPB | 3 | REST | Rest |
|
| WASHOUT 1 | | 1 | EX2 | TA | A-U-B | TPA-UTP-TPB | 4 | UTP | Usual |
|
| STUDY PRODUCT EXPOSURE 2 | | 12 | EX2 | TA | A-U-B | TPA-UTP-TPB | 5 | REST | Rest |
|
| WASHOUT 2 | | 13 | EX2 | TA | A-B-U | TPA-UTP-TPB | 6 | TPB | Prod B |
|
| STUDY PRODUCT EXPOSURE 3 | | 14 | EX2 | TA | A-B-U | TPA-UTP-TPB | 7 | FU | Follow-up |
|
| FOLLOW-UP | | 15 | EX2 | TA | A-B-U | TPA-TPB-Usual | 1 | SCRN | Screen | Randomized to TBA - TPB – Usual |
| SCREENING | | 16 | EX2 | TA | A-B-U | TPA-TPB-Usual | 2 | TPA | Prod A |
|
| STUDY PRODUCT EXPOSURE 1 | | 17 | EX2 | TA | A-B-U | TPA-TPB-Usual | 3 | REST | Rest |
|
| WASHOUT 1 | | 18 | EX2 | TA | A-B-U | TPA-TPB-Usual | 4 | TPB | Prod B |
|
| STUDY PRODUCT EXPOSURE 2 | | 19 | EX2 | TA | A-B-U | TPA-TPB-Usual | 5 | REST | Rest |
|
| WASHOUT 2 | | 20 | EX2 | TA | A-B-U | TPA-TPB-Usual | 6 | UTP | Usual |
|
| STUDY PRODUCT EXPOSURE 3 | | 21 | EX2 | TA | A-B-U | TPA-TPB-Usual | 7 | FU | Follow-up |
|
| FOLLOW-UP | |
|